Sign in
NEUP Stock Price, Chart, Stats & News
Neuphoria Therapeutics Inc.
Save
23.29M
Market cap
–
Current P/E
–
Forward P/E
NEUP chart
1M
3M
1Y
5Y
Loading chart...
Fundamentals
Gross margin | 94.74% |
Operating margin | -13728.73% |
Pretax margin | -10250.46% |
Net margin | -4546.55% |
Effective tax rate | 55.65% |
ROA | -1020.11% |
ROE | -1538.29% |
D/E | 0.00x |
Interest coverage ratio | – |
NEUP valuation
P/E | – |
P/S | 0.94x |
P/B | 0.63x |
P/CF | 0.25x |
P/FCF | 0.10x |
P/OCF | 0.25x |
PEG | -0.01x |
EV multiple | -0.04x |
About
Neuphoria Therapeutics, Inc. is a biotechnology company currently advancing treatments through clinical trials. Its core mission involves pioneering therapies specifically engineered to address the intricate requirements of individuals living with neuropsychiatric disorders. The company was established on December 23, 2024, and its main corporate offices are located in Burlington, Massachusetts.
Similar securities
Based on sector and market capitalization
Report issue